Craig Rubens is a co-founder of GAPPS through Seattle Children’s Hospital. An internationally recognized infectious disease expert, Craig led GAPPS' work in program development and strategic partnerships that leverage cross-disciplinary science to accelerate a discovery-to-delivery pipeline for improving maternal and newborn care and ultimately preventing prematurity and stillbirth. Craig is a professor of pediatrics and global health at the University of Washington School of Medicine. He is a member of many prestigious medical and scientific societies, including the American Pediatric Society and American Society of Clinical Investigators. He is on the Board of Scientific Counselors for the National Institute for Allergy and Infectious Diseases and has been a consultant and reviewer for the Bill & Melinda Gates Foundation, FDA, CDC, NIH, and other international funding organizations, along with many high-profile scientific journals. He is on the editorial board for the journal PLOS ONE.
Jack Faris earned a B.A. from the University of Washington and a Ph.D. in sociology from the University of Chicago. Following military service, he was associate professor at Towson University in Baltimore, with tenure. He served as Executive Vice President and General Manager at Cole & Weber advertising for eleven years, leading the agency's largest account, Boeing. He then joined the Bill & Melinda Gates Foundation as Director of Community Strategies. From 2000 to 2004, he was the University of Washington's Vice President for University Relations, and served as President of the Washington Biotechnology & Biomedical Association from 2005-2009. He was CEO of the Pacific Northwest Diabetes Research Institute from 2011 to 2012 and has also undertaken a variety of consulting roles and pro bono projects. Currently, Jack is a Senior Counselor with APCO Worldwide.
Thomas N. Hansen received his MD and completed his pediatric residency and neonatology training at Baylor College of Medicine in Houston, TX. He furthered his education by completing a fellowship in pediatric pulmonary diseases at the Cardiovascular Research Institute of the University of California at San Francisco and returned to Baylor where he advanced to Professor of Pediatrics and Chief of the Section of Neonatology. He also held the Texas Children’s Hospital Foundation Endowed Chair in Neonatology and served as Vice-Chairman of the Department for Research and Program Director for the Child Health Research Center. In 1995, Dr. Hansen was named Chairman of the Department of Pediatrics at the Ohio State University College of Medicine and Medical Director of Columbus Children’s Hospital. In 1997, he was named Chief Executive Officer of Columbus Children’s Hospital. During his ten-years as CEO, Columbus Children’s (now Nationwide Children’s) became one of the nation’s five largest, free-standing children’s hospitals and one of the ten largest free-standing pediatric research centers. In 2005, Dr. Hansen became CEO of Seattle Children's Hospital & Regional Medical Center, where he worked to help the hospital achieve it vision delivering the highest quality healthcare to all children regardless of their family’s ability to pay. Under Dr. Hansen’s leadership, Seattle Children’s Hospital was consistently rated as one of the nation’s best children’s hospitals by U.S. News & World Report and achieved “Magnet Status” by the American Nurses Association. Dr. Hansen retired as CEO of Seattle Children’s in 2015, and returned to the laboratory to focus on developing interventions to reduce the mortality of premature infants born in resource limited settings.
Andrew Ruud currently works at Amazon where he leads Amazon Business’ Strategic Business Development engagements including negotiated partnerships, source code licenses and other atypical, inorganic growth opportunities. Prior to his current role, Andrew worked for nearly five years on Amazon’s Corporate Development team where he sourced, structured, negotiated and executed acquisitions for business organizations across the company. Prior to Amazon, Andrew lived in New York City where he worked in the financial industry. Andrew graduated from Georgetown University where he received a B.S. in Accounting and a B.S. in Finance.
Dr. Litch is executive director and chief research officer of GAPPS. Dr. Litch’s work in global health began more than 25 years ago and he has lived and worked in a number of settings in Africa and Asia in frontline positions that ranged from medical officer in remote district hospitals, to NGO program director, to senior advisor for the Ministry of Health. He has held scientific and technical positions with GAPPS, PATH, CDC, University of Washington, and Johns Hopkins University/Jhpiego. At GAPPS, Dr. Litch led the Perinatal Interventions Program and served as principle investigator for a number of implementation science activities in Africa and Asia. At PATH, Dr. Litch was the Senior Newborn, Child and Maternal Health Specialist, where he directed a broad portfolio of innovative implementation research, maternal/newborn/child health and technology projects, and was PATH's lead on the USAID BASICS child survival program. At JHPIEGO, he was senior advisor to the flagship USAID Maternal Newborn Health Program and the USAID Training in Reproductive Health Program. He has been a consultant and a reviewer for the WHO, the USAID Maternal Child Survival Program, the Bill & Melinda Gates Foundation, and other global health organizations. Dr. Litch leads the PTB/LBW Global Technical Working Group, and serves on several international task forces, committees, advisory councils, and journal editorial boards. He is principle investigator and co-investigator to many applied research projects in Asia and Africa related to maternal, newborn health and stillbirth, and teaches in the areas of implementation science, evaluation, metrics and perinatal health.
Carol Dahl is the Executive Director of the Lemelson Foundation and leads the Foundation’s work to use the power of invention to improve lives. The Foundation inspires and enables the next generation of inventors and invention-based enterprises to promote economic growth in the U.S., and to help solve social and economic problems for the poorest populations in developing countries. Prior to joining the Lemelson Foundation, Carol worked for the Bill & Melinda Gates Foundation, where she built platform discovery innovation programs Grand Challenges in Global Health and Grand Challenges Explorations. Previously, Carol served as Vice President for Strategic Partnerships at Biospect Inc. (now Pathworks Diagnostics). From 1990 to 2001, Carol worked at the U.S. National Institutes of Health in several capacities, including founding Director of the Office of Technology and Industrial Relations at the National Cancer Institute and Program Director at the National Center for Human Genome Research. Dahl received a bachelor's degree from the University of Iowa and master’s and doctoral degrees from the University of Wisconsin-Madison. She received postdoctoral training at the Karolinska Institute in Stockholm and the Immunobiology Research Center at the University of Minnesota and served on the faculty of the Pittsburgh Cancer Institute and University of Pittsburgh.
Jack Faris earned a B.A. from the University of Washington and a Ph.D. in sociology from the University of Chicago.
Following military service, he was associate professor at Towson University in Baltimore, with tenure. He worked eleven years at Cole & Weber advertising, leading the agency's largest account, Boeing, and serving as Executive Vice President and General Manager. He then joined the Bill & Melinda Gates Foundation as Director of Community Strategies. From 2000 to 2004, he was the University of Washington's Vice President for University Relations. He served as President of the Washington Biotechnology & Biomedical Association from 2005-2009. He was CEO of the Pacific Northwest Diabetes Research Institute from 2011 to 2012 and has also undertaken a variety of consulting roles and pro bono projects. Currently, Jack is a Senior Counselor with APCO Worldwide.
Richard is the Executive Director of the Grants, Innovation and Product Development groups at the South African Medical Research Council (SAMRC) which includes the revolutionary Strategic Health Innovation Partnerships (SHIP) unit focusing on product development. The unit manages more than 200 grants ranging from small independent research awards to major international programs seeking to develop new drugs vaccines and medical devices. The majority of the SAMRC programs focus on HIV, Tuberculosis and Malaria – including drug resistance.
Richard has held a number of international positions and specializes in establishing international research partnerships. These range from drug discovery (target discovery, high throughput screening, medicinal chemistry, ADMET and pharmacology for a wide range of therapeutic areas), medical devices and vaccines. Richard completed his PhD at the University of Cape Town and his post-doctoral fellowship at the University of Cambridge. Prior to his time at the MRC, Richard spend two years at the Technology Innovation Agency as a Senior Investment Case Specialist and 10 years at BioFocus, a UK based pharmaceutical drug discovery Contract Research Organization where he moved from the bench to the Global Head of Business Development and marketing. He is also a chartered marketer.
Leith is Vice Chair at the MDG Health Alliance, a special initiative of the UN Special Envoy for Financing the Health Millennium Development Goals in support of the UN Secretary General’s Every Woman Every Child movement.
Leith founded and leads several initiatives at the Alliance including the Pneumonia Innovations Team, the Public-Private Partnership to Prevent Preterm Birth, and the Real Conversations About Contraception Campaign, and has led engagement with the Faith Alliance for Health, Does 1+1= 3: The Integration Hypothesis, the Global Nutrition Report, and the Every Newborn Action Plan where her efforts to engage the private sector resulted in a record number of new commitments. Leith has also conceived of and led the release of several new reports including Pushing the Pace: Progress and Challenges in the Fight Against Child Pneumonia and the Ultimate Investment in the Future: Corporate Engagement in Newborn Health and Development. She is currently working on new initiatives to increase rates of breastfeeding in countries struggling with high newborn deaths, and to deepen the engagement the extractives industry in the achievement of the new Sustainable Development Goals. Leith has authored numerous articles relating to the achievement of global heath goals.
Leith is also an investor in several non-proﬁt organizations that empower women, the founder and chair of “Isha Koach", a giving circle that invests in women social entrepreneurs, and a member of the Peace and Security Funders Group. She served on the US Board of GAVI, The Vaccine Alliance and in several positions with the Australian Government, including as Policy Advisor and Speechwriter to the Deputy Prime Minister and Minister for Health, as Economic Adviser to the Leader of the Opposition, and as Chief of Staff to the Shadow Minister for Social Security and the Status of Women. Leith holds a Masters in Public Administration from the Harvard Kennedy School, a Masters in Business Administration from the Chinese University of Hong Kong and a First-Class Honors Degree from the University of Queensland.
Frank Greer is the founding partner of GMMB. He has more than 40 years of experience in communications and advertising, serving clients that include major foundations, public interest groups, labor organizations, corporations, and successful candidates for Congress, governor, Senate and the presidency. Since 1972, Frank has provided counsel and communications services to public interest causes and foundations, political campaigns as all levels, and international governments around the world.
Dean Williams’ research interests lie principally, but not exclusively, in the field of reproductive and perinatal epidemiology. She has spent the last two decades focused on integrating epidemiological, biological and molecular approaches into rigorously designed clinical epidemiology research projects that have led to greater understandings of the etiology and pathophysiology of placental abruption, gestational diabetes, and preeclampsia. To date, much of her work has been focused on advancing knowledge of the etiology of selected highly relevant, but fairly understudied perinatal outcomes. She has also sought to expand the literature by searching for and then confirming novel/non-traditional risk factors of those outcomes. Her research programs have been largely funded by a number of research awards from the National Institutes of Health. To date, she has authored or co-authored 240 original research reports. Dean Williams is Principal Investigator of several large National Institutes of Health-funded projects.